EP1436329A4 - Anti-pdgf antibodies and methods for producing engineered antibodies - Google Patents

Anti-pdgf antibodies and methods for producing engineered antibodies

Info

Publication number: EP1436329A4
Authority: EP; European Patent Office
Prior art keywords: antibodies; methods; pdgf; producing engineered; engineered antibodies
Prior art date: 2001-09-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP02775937A

Other languages

German (de)

French (fr)

Other versions

EP1436329A1 (en

Inventor

Katherine S Bowdish

Shana Frederickson

Anke Kretz-Rommel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alexion Pharmaceuticals Inc

Original Assignee

Alexion Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-20

Filing date

2002-09-20

Publication date

2005-04-27

2002-09-20 Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc

2004-07-14 Publication of EP1436329A1 publication Critical patent/EP1436329A1/en

2005-04-27 Publication of EP1436329A4 publication Critical patent/EP1436329A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP02775937A 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies Withdrawn EP1436329A4 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US32353701P	2001-09-20	2001-09-20
US32354401P	2001-09-20	2001-09-20
US323537P		2001-09-20
US323544P		2001-09-20
US37999402P	2002-05-13	2002-05-13
US379994P		2002-05-13
PCT/US2002/030086 WO2003025019A1 (en)	2001-09-20	2002-09-20	Anti-pdgf antibodies and methods for producing engineered antibodies

Publications (2)

Publication Number	Publication Date
EP1436329A1 EP1436329A1 (en)	2004-07-14
EP1436329A4 true EP1436329A4 (en)	2005-04-27

Family

ID=27406282

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP02775937A Withdrawn EP1436329A4 (en)	2001-09-20	2002-09-20	Anti-pdgf antibodies and methods for producing engineered antibodies

Country Status (4)

Country	Link
EP (1)	EP1436329A4 (en)
JP (1)	JP2005512962A (en)
CA (1)	CA2460587A1 (en)
WO (1)	WO2003025019A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7393648B2 (en)	2001-12-03	2008-07-01	Alexion Pharmaceuticals, Inc.	Hybrid antibodies
SI1461428T1 (en)	2001-12-03	2012-07-31	Alexion Pharma Inc	Method for producing hybrid antibodies
CA2475735A1 (en) *	2002-02-11	2003-09-18	Alexion Pharmaceuticals, Inc.	Immunotherapeutics for biodefense
MXPA05011406A (en) *	2003-04-23	2005-12-12	Medarex Inc	Humanized antibodies to interferon alpha receptor-1 (ifnar-1).
SI1660057T1 (en)	2003-08-27	2012-10-30	Ophthotech Corp	Combination therapy for the treatment of ocular neovascular disorders
AU2005227326B2 (en) *	2004-03-24	2009-12-03	Xencor, Inc.	Immunoglobulin variants outside the Fc region
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
EP2280997A2 (en) *	2008-04-18	2011-02-09	Xencor, Inc.	Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US9896730B2 (en)	2011-04-25	2018-02-20	OSI Pharmaceuticals, LLC	Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
SG10201710574UA (en)	2012-03-15	2018-02-27	Janssen Biotech Inc	Human anti-cd27 antibodies, methods and uses
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
EP2867360B1 (en) *	2012-06-28	2019-05-08	Molecular Partners AG	Designed ankyrin repeat proteins binding to platelet-derived growth factor
BR112015006929A2 (en)	2012-09-27	2017-07-04	Allergan Inc	biodegradable drug delivery systems for sustained protein release
CA2902547A1 (en)	2013-03-14	2014-09-25	Allergan, Inc.	Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
SG10201708882TA (en)	2013-07-12	2017-12-28	Ophthotech Corp	Methods for treating or preventing ophthalmological conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999024059A1 (en) *	1997-11-07	1999-05-20	Massachusetts Institute Of Technology	Pdgf-mediated microvascular communication and methods of use thereof
WO1999029888A1 (en) *	1997-12-05	1999-06-17	The Scripps Research Institute	Humanization of murine antibody
US6180370B1 (en) *	1988-12-28	2001-01-30	Protein Design Labs, Inc.	Humanized immunoglobulins and methods of making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5817310A (en) *	1991-12-02	1998-10-06	Cor Therapeutics, Inc.	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) *	1993-02-25	1999-11-02	Zymogenetics, Inc.	Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5700823A (en) *	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers

2002
- 2002-09-20 JP JP2003528864A patent/JP2005512962A/en not_active Withdrawn
- 2002-09-20 CA CA002460587A patent/CA2460587A1/en not_active Abandoned
- 2002-09-20 EP EP02775937A patent/EP1436329A4/en not_active Withdrawn
- 2002-09-20 WO PCT/US2002/030086 patent/WO2003025019A1/en active Application Filing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6180370B1 (en) *	1988-12-28	2001-01-30	Protein Design Labs, Inc.	Humanized immunoglobulins and methods of making the same
WO1999024059A1 (en) *	1997-11-07	1999-05-20	Massachusetts Institute Of Technology	Pdgf-mediated microvascular communication and methods of use thereof
WO1999029888A1 (en) *	1997-12-05	1999-06-17	The Scripps Research Institute	Humanization of murine antibody

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROECKER M ET AL: "Excessive activation of tyrosine kinases leads to inhibition of proliferation in a thyroid carcinoma cell line.", LIFE SCIENCES. 1998, vol. 63, no. 26, 1998, pages 2373 - 2386, XP002307362, ISSN: 0024-3205 *
CHUNTHARAPAI ANAN ET AL: "Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE", CYTOKINE, vol. 15, no. 5, 7 September 2001 (2001-09-07), pages 250 - 260, XP002307361, ISSN: 1043-4666 *
See also references of WO03025019A1 *
SHIMIZU S ET AL: "In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, no. 12, December 2000 (2000-12-01), pages 1285 - 951, XP002960893, ISSN: 0910-5050 *
WU H ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP004461859, ISSN: 0022-2836 *

Also Published As

Publication number	Publication date
JP2005512962A (en)	2005-05-12
WO2003025019A1 (en)	2003-03-27
WO2003025019A8 (en)	2004-04-01
CA2460587A1 (en)	2003-03-27
WO2003025019A9 (en)	2004-05-06
EP1436329A1 (en)	2004-07-14

Publication	Publication Date	Title
EP1436329A4 (en)	2005-04-27	Anti-pdgf antibodies and methods for producing engineered antibodies
EP1432444A4 (en)	2005-11-02	Anti-a-beta antibodies
HK1074206A1 (en)	2005-11-04	Anti-trail-r antibodies
HK1065471A1 (en)	2005-02-25	Methods of administering anti-tnf-alpha antibodies
AU2002346641A8 (en)	2003-06-17	Apertured non-woven composites and method for making
EP1635872A4 (en)	2008-01-02	Antibodies and fusion proteins that include engineered constant regions
IL157142A0 (en)	2004-02-08	Modified antibodies and methods of use
EP1514928A4 (en)	2009-08-05	Method for producing antibodies
IL225633A0 (en)	2014-03-31	Anti-alpha-v-beta - 6 antibodies and uses thereof
EP1551447A4 (en)	2007-03-07	Anti-addl antibodies and uses thereof
AU4002001A (en)	2001-09-12	High potency recombinant antibodies and method for producing them
PT1361893E (en)	2013-01-24	Modified anti-egfr antibodies with reduced immunogenicity
HUP0402333A3 (en)	2007-05-02	Modified anti-tnf alpha antibody
GB0128287D0 (en)	2002-01-16	Novel method and compounds
TWI346203B (en)	2011-08-01	Antibody pair screening methods
AU2002340167A8 (en)	2003-06-17	Anti-hla-dr antibodies and the methods of using thereof
AU2002365649A8 (en)	2003-06-17	Anti-dota antibody
GB2387599B (en)	2005-08-10	Methods for producing antibodies
AU2002359495A8 (en)	2003-06-17	Anti-tnf antibodies, compositions, methods and uses
AU2002367943A8 (en)	2003-12-22	Improved reagents and methods for producing parvoviruses
IL166063A0 (en)	2006-01-15	Antibodies and uses thereof
TWI318239B (en)	2009-12-11	Methods for producing novel medaka and novel medaka
GB0221940D0 (en)	2002-10-30	Antibody and screening method
GB0119553D0 (en)	2001-10-03	Antibodies
GB0118696D0 (en)	2001-09-19	Novel antibodies

Legal Events

Date	Code	Title	Description
2004-05-28	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-07-14	17P	Request for examination filed	Effective date: 20040316
2004-07-14	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
2004-07-14	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2005-04-27	A4	Supplementary search report drawn up and despatched	Effective date: 20050308
2006-10-04	17Q	First examination report despatched	Effective date: 20050808
2008-05-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2008-06-11	18D	Application deemed to be withdrawn	Effective date: 20071219